• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·India·Healthcare·SURAKSHA.BO
Share

SURAKSHA DIAGNOSTIC LIMITED Stocks

₹ 314.95Last Updated 22.05.2026

Issuer Rating

3/7
Performance

Modest

Risk

Considerable

Recommendation

Sell

Market Cap

₹ 164.68M

₹ 314.95
Key Takeaways

Risk factor

Very poor trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very low or no dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Established in 1992 as Suraksha Diagnostics & Eye Centre (P) Ltd. in Kolkata, they started as one of the first diagnostic centers in Kolkata to provide all pathology and radiology services under one roof. This convenience, along with their unwavering commitment to accuracy and service, resulted in steady growth and popularity. Within 3 years they could confidently open a second Center at Siliguri, in North Bengal, which remains the largest such facility in the region, and today serves not only to patients from North Bengal, but also neighbouring States and countries. Since then they have grown steadily across Bengal, Bihar, and Delhi NCR.

Company Valuation

Overvalued
2/7

Considering past and projected metrics, the stock is 'expensive' compared to its peers. Specifically, the stock is fairly valued on P/E, neutral on EV/EBITDA, overpriced

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Slightly negative
3/7

The average target price of SURAKSHA.BO is 310 and suggests 0% upside potential. Usually, this means a HOLD recommendation among investment firms. This neutral recommenda

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

24.05.2026 21:00

SpaceX's secrets, OpenAI's listing and their fight for investors: what's important about the IPO by Ma. 24

24.05.2026 15:01

Millionaires are often unhappy. What can this paradox teach an investor?

24.05.2026 02:09

Deal with Iran that would open the Strait of Hormuz is almost agreed upon - Trump

23.05.2026 16:01

Highlights in small-caps: Ebola vaccine, SpaceX IPO beneficiaries, newcomers to Russell

23.05.2026 13:01

Highlights of the week: SpaceX development plans, Nvidia reporting, new Nebius competitor

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn
  • X (Twitter)
  • LinkedIn
Oninvest© 2026